Status:
COMPLETED
Gene Expression Profiling in Type 1 Diabetes
Lead Sponsor:
Children's Mercy Hospital Kansas City
Conditions:
Type 1 Diabetes Mellitus
Eligibility:
All Genders
7-14 years
Brief Summary
One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can ai...
Detailed Description
The hypothesis is that viral responsive genes are up-regulated prior to the onset of symptoms of Type 1 Diabetes (T1DM) and may correlate with increased expression of interferon alpha. Both genetic a...
Eligibility Criteria
Inclusion
- Male and female subjects 7-14 years of age
- New onset T1DM
- Five years post onset of T1DM
- Participant in the TrialNet initiative and either antibody positive or antibody negative sibling control
- Body weight sufficient to tolerate an additional 15ml (1 tbsp) blood loss
Exclusion
- Subjects who do not meet the criteria above
- Subjects who have received steroids or other immunosuppressive therapy within the 6 months prior to enrollment into the study
Key Trial Info
Start Date :
June 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2008
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00330954
Start Date
June 1 2006
End Date
April 1 2008
Last Update
March 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108